Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vespula spp. venom allergens
- Development stage
- Phase 4
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Alutard SQ 802 Vespula spp. is a subcutaneous allergen immunotherapy (SCIT) product developed by ALK (ALK-Abelló) for the treatment of IgE-mediated wasp venom allergy. It consists of a standardized extract of venom from multiple *Vespula* species, including *V. germanica*, *V. alascensis*, *V. maculifrons*, *V. flavopilosa*, *V. pensylvanica*, and *V. squamosa*. The allergens are adsorbed onto aluminium hydroxide, which serves as an adjuvant to create a depot effect, allowing for slow release and prolonged immune stimulation. The primary mechanism of action involves inducing immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile, characterized by a decrease in specific IgE levels and an increase in protective IgG4 antibodies. This desensitization process significantly reduces the risk of systemic anaphylactic reactions upon subsequent stings. It is currently used in various clinical protocols, including accelerated outpatient regimens, to achieve maintenance dosing and clinical efficacy more rapidly.
- Brand names
- Alutard SQ 802 Vespula spp.Alutard SQAlutard SQ Wasp
- Other names
- Vespula spp. venom extractWasp venom immunotherapy
02
Targets
Hyaluronan and related glycosaminoglycans (HA and GAGs)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on vespula spp. venom allergens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vespula spp. venom allergens.